|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249.
2021.PubMed/NCBI
|
|
2
|
Moris D, Palta M, Kim C, Allen PJ, Morse
MA and Lidsky ME: Advances in the treatment of intrahepatic
cholangiocarcinoma: An overview of the current and future
therapeutic landscape for clinicians. CA Cancer J Clin. 73:198–222.
2023.PubMed/NCBI
|
|
3
|
Banales JM, Marin JJG, Lamarca A,
Rodrigues PM, Khan SA, Roberts LR, Cardinale V, Carpino G, Andersen
JB, Braconi C, et al: Cholangiocarcinoma 2020: The next horizon in
mechanisms and management. Nat Rev Gastroenterol Hepatol.
17:557–588. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Greten TF, Schwabe R, Bardeesy N, Ma L,
Goyal L, Kelley RK and Wang XW: Immunology and immunotherapy of
cholangiocarcinoma. Nat Rev Gastroenterol Hepatol. 20:349–365.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Mazzaferro V, Gorgen A, Roayaie S, Droz
Dit Busset M and Sapisochin G: Liver resection and transplantation
for intrahepatic cholangiocarcinoma. J Hepatol. 72:364–377. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kelley RK, Bridgewater J, Gores GJ and Zhu
AX: Systemic therapies for intrahepatic cholangiocarcinoma. J
Hepatol. 72:353–363. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Brindley PJ, Bachini M, Ilyas SI, Khan SA,
Loukas A, Sirica AE, The BT, Wongkham S and Gores GJ:
Cholangiocarcinoma. Nat Rev Dis Primers. 7:652021. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Vogel A, Segatto O, Stenzinger A and
Saborowski A: FGFR2 inhibition in cholangiocarcinoma. Annu Rev Med.
74:293–306. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wang T, Shi X, Wang Z, Liu X, Zhang G, Zhu
Q, Mi L and Wang R: Overexpression of PTP4A1 is associated with
poor overall survival in non-small cell lung cancer. Int J Clin Exp
Pathol. 11:3583–3590. 2018.PubMed/NCBI
|
|
10
|
Sun JP, Luo Y, Yu X, Wang WQ, Zhou B,
Liang F and Zhang ZY: Phosphatase activity, trimerization, and the
C-terminal polybasic region are all required for PRL1-mediated cell
growth and migration. J Biol Chem. 282:29043–29051. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bai Y, Luo Y, Liu S, Zhang L, Shen K, Dong
Y, Walls CD, Quilliam LA, Wells CD, Cao Y and Zhang ZY: PRL-1
protein promotes ERK1/2 and RhoA protein activation through a
non-canonical interaction with the Src homology 3 domain of p115
Rho GTPase-activating protein. J Biol Chem. 286:42316–42324. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Liu LZ, He YZ, Dong PP, Ma LJ, Wang ZC,
Liu XY, Duan M, Yang LX, Shi JY, Zhou J, et al: Protein tyrosine
phosphatase PTP4A1 promotes proliferation and
epithelial-mesenchymal transition in intrahepatic
cholangiocarcinoma via the PI3K/AKT pathway. Oncotarget.
7:75210–75220. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Li X, Ma N, Zhang Y, Wei H, Zhang H, Pang
X, Li X, Wu D, Wang D, Yang Z and Zhang S: Circular RNA circNRIP1
promotes migration and invasion in cervical cancer by sponging
miR-629-3p and regulating the PTP4A1/ERK1/2 pathway. Cell Death
Dis. 11:3992020. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Luo Y, Liang F and Zhang ZY: PRL1 promotes
cell migration and invasion by increasing MMP2 and MMP9 expression
through Src and ERK1/2 pathways. Biochemistry. 48:1838–1846. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sacchetti C, Bai Y, Stanford SM, Di
Benedetto P, Cipriani P, Santelli E, Piera-Velazquez S, Chernitskiy
V, Kiosses WB, Ceponis A, et al: PTP4A1 promotes TGFβ signaling and
fibrosis in systemic sclerosis. Nat Commun. 8:10602017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jin S, Wang K, Xu K, Xu J, Sun J, Chu Z,
Lin D, Koeffler PH, Wang J and Yin D: Oncogenic function and
prognostic significance of protein tyrosine phosphatase PRL-1 in
hepatocellular carcinoma. Oncotarget. 5:3685–3696. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hu H, Ye L and Liu Z: GINS2 regulates the
proliferation and apoptosis of colon cancer cells through PTP4A1.
Mol Med Rep. 25:1172022. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Liu B, Si W, Wei B, Zhang X and Chen P:
PTP4A1 promotes oral squamous cell carcinoma (OSCC) metastasis
through altered mitochondrial metabolic reprogramming. Cell Death
Discov. 9:3602023. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lu JW, Chang JG, Yeh KT, Chen RM, Tsai JJ,
Su WW and Hu RM: Increased expression of PRL-1 protein correlates
with shortened patient survival in human hepatocellular carcinoma.
Clin Transl Oncol. 14:287–293. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Li O, Jiang B, Yi WM, Zhang Y, Yang PZ,
Guo C, Sun ZP and Peng C: LncRNA NEAT1 promotes cell proliferation,
migration, and invasion via the miR-186-5p/PTP4A1 axis in
cholangiocarcinoma. Kaohsiung J Med Sci. 37:379–391. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bekki Y, Von Ahrens D, Takahashi H,
Schwartz M and Gunasekaran G: Recurrent intrahepatic
cholangiocarcinoma-review. Front Oncol. 21:7768632021. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sapisochin G, Ivanics T and Heimbach J:
Liver transplantation for intrahepatic cholangiocarcinoma: Ready
for prime time? Hepatology. 75:455–472. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Edeline J, Touchefeu Y, Guiu B, Farge O,
Tougeron D, Baumgaertner I, Ayav A, Campillo-Gimenez B, Beuzit L,
Pracht M, et al: Radioembolization plus chemotherapy for first-line
treatment of locally advanced intrahepatic cholangiocarcinoma: A
phase 2 clinical trial. JAMA Oncol. 6:51–59. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Shi GM, Huang XY, Wu D, Sun HC, Liang F,
Ji Y, Chen Y, Yang GH, Lu JC, Meng XL, et al: Toripalimab combined
with lenvatinib and GEMOX is a promising regimen as first-line
treatment for advanced intrahepatic cholangiocarcinoma: A
single-center, single-arm, phase 2 study. Signal Transduct Target
Ther. 8:1062023. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Giménez-Mascarell P, Oyenarte I, Hardy S,
Breiderhoff T, Stuiver M, Kostantin E, Diercks T, Pey AL,
Ereño-Orbea J, Martínez-Chantar ML, et al: Structural basis of the
oncogenic interaction of phosphatase PRL-1 with the magnesium
transporter CNNM2. J Biol Chem. 292:786–801. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Reich R, Hadar S and Davidson B:
Expression and clinical role of protein of regenerating liver (PRL)
phosphatases in ovarian carcinoma. Int J Mol Sci. 12:1133–1145.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Fu Y, Li B, Huang R, Ji X and Bai WK: Long
noncoding RNA DLEU2 promotes growth and invasion of hepatocellular
carcinoma by regulating miR-30a-5p/PTP4A1 axis. Pathol Res Pract.
238:1540782022. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhang JX, Mai SJ, Huang XX, Wang FW, Liao
YJ, Lin MC, Kung HF, Zeng YX and Xie D: MiR-29c mediates
epithelial-to-mesenchymal transition in human colorectal carcinoma
metastasis via PTP4A and GNA13 regulation of β-catenin signaling.
Ann Oncol. 25:2196–2204. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zou J, Ma Q, Gao C, Yang M, Wen J, Xu L,
Guo X, Zhong X and Duan Y: WTAP promotes proliferation of
esophageal squamous cell carcinoma via m6A-dependent epigenetic
promoting of PTP4A1. Cancer Sci. 115:2254–2268. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chen M, Chi Y, Chen H and Zhao L: Long
non-coding RNA USP30-AS1 aggravates the malignant progression of
cervical cancer by sequestering microRNA-299-3p and thereby
overexpressing PTP4A1. Oncol Lett. 22:5052021. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Glaviano A, Foo ASC, Lam HY, Yap KCH,
Jacot W, Jones RH, Eng H, Nair MG, Makvandi P, Geoerger B, et al:
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies
in cancer. Mol Cancer. 22:1382023. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Parsons R: Discovery of the PTEN tumor
suppressor and its connection to the PI3K and AKT oncogenes. Cold
Spring Harb Perspect Med. 10:a0361292020. View Article : Google Scholar : PubMed/NCBI
|
